In re McKesson Corporation Derivative Litigation

Court: United States District Court, Northern District of California, Oakland Division
Case Number: 4:17-cv-01850-CW
Judge: Hon. Claudia Wilken
Case Contacts: Mark Lebovitch, David Wales, Alla Zayenchik

This derivative action is pending in the United States District Court, Northern District of California, Oakland Division, against current and former officers and directors of McKesson Corporation (“McKesson” or the “Company”). This action is brought by several stockholders of McKesson. BLB&G represents both the Police & Fire Retirement System City of Detroit and Amalgamated Bank, as Trustee for Longview Largecap 500 Index Fund and Longview Largecap 500 Index VEBA Fund. As set forth below, there is a proposed settlement for $175 million plus substantial corporate governance reforms.

The Complaint alleges breaches of fiduciary duties by the Company’s board of directors and senior executive officers for failure to exercise oversight of McKesson’s compliance with the Controlled Substances Act and related regulations (collectively “the CSA”), as well as a 2008 settlement with the Drug Enforcement Administration (“DEA”). The relevant provisions of the CSA and the 2008 DEA settlement were specifically designed to prevent the diversion of controlled substances, including by requiring McKesson to have a monitoring system for suspicious orders of controlled substances and also to report the suspicious orders to the DEA. The Complaint alleges that McKesson failed to comply with the CSA or the 2008 DEA settlement, and as a result, entered into a 2017 settlement with the DEA and the United States Department of Justice (“DOJ”), for failing to comply with the CSA and failing to monitor and report suspicious orders of controlled substances to the DEA. McKesson paid $150 million as part of the 2017 settlement with the DEA and DOJ and its licenses to distribute controlled substances were temporarily suspended at certain of its distribution facilities. In addition, McKesson was sued in the National Opioid MDL, for contributing to the national opioid crisis by failing to comply with the CSA and failing to report suspicious orders. As a result, Plaintiffs seek to hold Defendants liable for their breaches of fiduciary duty, which have already caused substantial damages to the Company, injury to its reputation, and subjected it to numerous investigations and lawsuits.

On May 14, 2018, the Court entered an order denying the defendants’ motion to stay, and denying in part and granting in part the defendants’ motion to dismiss. Click here for a copy of the decision. The Defendants moved for partial reconsideration of the decision denying the motion to dismiss. On June 21, 2018, the Court denied that motion. On September 12, 2018, the plaintiffs filed a second amended complaint. Click here for a copy of the Complaint.

McKesson set up a Special Litigation Committee (“SLC”), and on September 17, 2018, the SLC moved to stay the Action. After briefing and oral argument, on November 13, 2018, the Court denied the SLC’s motion to stay, except for delaying the start of depositions. Click here for a copy of the decision. Following this decision, the parties commenced discovery.

On December 27, 2019, the Plaintiffs submitted a motion for preliminary approval of a proposed settlement of $175 million, plus substantial corporate governance reforms. Click here for a copy of the stipulation of settlement. The Court granted preliminary approval of the proposed settlement on January 31, 2020, and has scheduled the final approval hearing for April 21, 2020, at 2:30 pm. Click here for the preliminary approval order, here for the revised short form notice, and here for the revised long form notice.

Other Cases of Interest

  • Oracle Corporation
    Northern District of California John Rizio-Hamilton, Mark Lebovitch, Jonathan D. Uslaner, Abe Alexander
  • Fluor Corporation
    Northern District of Texas Gerald H. Silk, Mark Lebovitch, Avi Josefson
  • CVR Refining
    Delaware Court of Chancery Mark Lebovitch, David Wales, Thomas James
  • Tile Shop
    Delaware Chancery Court Gregory V. Varallo, Mark Lebovitch, Christopher J. Orrico, Jacqueline Y. Ma
  • Pfizer, Inc.
    Southern District of New York Mark Lebovitch, David Wales, Jeroen van Kwawegen, Jonathan D. Uslaner
  • Allergan, Inc. (Proxy Violation)
    Central District of California Mark Lebovitch, Jeremy P. Robinson, Michael D. Blatchley, Richard D. Gluck, Edward G. Timlin
  • Intuitive Surgical Inc.
    Superior Court of the State of California, County of San Mateo David Wales, Mark Lebovitch, Edward G. Timlin
  • Virgin Media, Inc.
    County of New York: Commercial Division Mark Lebovitch, Jeroen van Kwawegen
  • Twenty-First Century Fox, Inc.
    Delaware Chancery Court Max W. Berger, Mark Lebovitch, David Wales, Rebecca E. Boon